Title:Recent Advances in Targeted Therapy for Glioma
Volume: 24
Issue: 13
Author(s): Lin Lin, Jinquan Cai*Chuanlu Jiang*
Affiliation:
- Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, No.246 XueFu Road, NanGang District, Harbin, Heilongjiang Province 150086,China
- Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, No.246 XueFu Road, NanGang District, Harbin, Heilongjiang Province 150086,China
Keywords:
Glioma, clinical trials, targeted therapy, cell signal transduction pathway, glioma stem cell,
Immunotherapy.
Abstract: Gliomas are the most common primary malignant brain tumors, which have a universally
fatal outcome. Current standard treatment for glioma patients is surgical removal followed
by radiotherapy and adjuvant chemotherapy. Due to therapeutic resistance and tumor
recurrence, efforts are ongoing to identify the molecules that are fundamental to regulate the
tumor progression and provide additional methods for individual treatment of glioma patients.
By studying the initiation and maintenance of glioma, studies focused on the targets of tyrosine
kinase receptors including EGFR, PDGFR and other crucial signal pathways such as
PI3K/AKT and RAS/RAF/MAPK pathway. Furthermore, recent advances in targeting immunotherapy
and stem cell therapy also brought numerous strategies to glioma treatment. This
article reviewed the researches focused on the advanced strategies of various target therapies
for improving the glioma treatment efficacy, and discussed the challenges and future directions
for glioma therapy.
